Sutro Biopharma (NASDAQ:STRO) Receives New $16.00 Price Target at Piper Sandler


Sutro Biopharma (NASDAQ:STRO – Get Review) had its price target raised by Piper Sandler to $16.00 in a research note released on Monday, Stock Target Advisor reports.

A number of other brokerages have also recently released reports on STRO. Wedbush lowered its price target on Sutro Biopharma from $30.00 to $20.00 in a Tuesday, May 10 research report. JMP Securities reaffirmed a Buy rating and issued a $20.00 price target on Sutro Biopharma shares in a Monday, June 6 research note. Finally, HC Wainwright reduced its price target on Sutro Biopharma from $35.00 to $30.00 in a Wednesday, May 11 research note.

Shares of STRO opened at $5.25 on Monday. Sutro Biopharma has a 52 week low of $3.33 and a 52 week high of $23.70. The company has a debt ratio of 0.06, a quick ratio of 5.90 and a current ratio of 5.90. The company’s 50-day moving average price is $4.81 and its two-hundred-day moving average price is $8.03. The company has a market capitalization of $246.40 million, a PE ratio of -2.13 and a beta of 0.91.

Sutro Biopharma (NASDAQ:STRO – Get Rating) last released quarterly earnings data on Monday, May 9. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.08). Sutro Biopharma had a negative net margin of 215.16% and a negative return on equity of 42.97%. Research analysts predict that Sutro Biopharma will post EPS of -3.27 for the current fiscal year.

A number of institutional investors and hedge funds have recently changed their holdings of STROs. Suvretta Capital Management LLC increased its stake in Sutro Biopharma by 53.1% during the first quarter. Suvretta Capital Management LLC now owns 3,732,400 shares of the company valued at $30,680,000 after purchasing an additional 1,294,605 ​​shares in the last quarter. BlackRock Inc. increased its position in Sutro Biopharma by 0.8% in the 1st quarter. BlackRock Inc. now owns 3,728,829 shares of the company valued at $30,650,000 after acquiring 28,786 additional shares last quarter. Eventide Asset Management LLC increased its position in Sutro Biopharma shares by 14.3% in the 4th quarter. Eventide Asset Management LLC now owns 2,708,975 shares of the company worth $40,310,000 after purchasing an additional 338,000 shares in the last quarter. State Street Corp increased its position in Sutro Biopharma shares by 66.1% in the first quarter. State Street Corp now owns 2,642,486 shares of the company worth $21,721,000 after purchasing an additional 1,051,649 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Sutro Biopharma shares by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 2,230,997 shares of the company worth $18,338,000 after purchasing an additional 113,190 shares in the last quarter. Institutional investors and hedge funds own 92.68% of the company’s shares.

About Sutro Biopharma (Get a rating)

Sutro Biopharma, Inc. operates as a clinical-stage drug discovery, development and manufacturing company. It focuses on creating therapeutic proteins for cancer and autoimmune diseases through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+. The Company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the CD74 cancer target for patients with multiple myeloma and non-Hodgkin’s lymphoma in Phase 1 clinical trials; and STRO-002, a folate receptor alpha-directed ADC for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.

Read more



Get news and reviews for Sutro Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Sutro Biopharma and related companies with MarketBeat.com’s free daily email newsletter.

About Catriona

Check Also

Blue Ocean Technologies integrates with Broadridge

Blue Ocean Technologies successfully integrates with Broadridge trading and connectivity solutions NEW YORK, Aug. 1, …